Watch Live

Tweet TWEET

Amarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical

Amarin Announces Submission of Supplemental New Drug Application for Novasep
as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today the submission of a Supplemental New Drug Application
(sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for
Novasep Group, S.A.S., through its subsidiary Finorga S.A.S., as an additional
Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.
Novasep is part of the previously disclosed Slanmhor consortium with which
Amarin announced a global supply agreement in 2012.

Novasep, a global leader in purification technologies and API manufacturing,
is building the world's largest chromatography plant using its proprietary
chromatography technologies to produce API on behalf of the Slanmhor
consortium and Amarin. Amarin anticipates the Novasep facility, located in
Mourenx, France, to be qualified and operational for manufacturing in 2014.

"This sNDA submission for Novasep brings to four the total number of suppliers
that are approved or in regulatory review for Vascepa API production,
including Nisshin Pharma, Inc. and following the recent FDA approvals of both
BASF and Chemport as API suppliers for the product," stated Joseph Zakrzewski,
Chairman and Chief Executive Officer of Amarin."The Novasep submission
represents an additional step toward the goal of expanding our global supply
chain to support expected Vascepa demand, diversify our supply base and ensure
cost-efficient supply.As previously stated, the continued addition of these
suppliers will potentially lead to API cost reductions of up to 50% or more
and help us reach a steady state gross margin as a percentage of product
revenues in the high seventies to low eighties."

This submission contributes to the planned expansion of the Vascepa
manufacturing supply chain and is additional progress toward Amarin's goal to
protect the commercial potential of Vascepa to beyond 2030 through a
combination of patent protection, regulatory exclusivity, trade secrets and by
taking advantage of manufacturing barriers to entry. Along with this planned
expansion in supply, Amarin's significant progress includes expansion of
patent protection for Vascepa in the United States with 27 Amarin patents
either issued or allowed and over 30 additional patent applications being
prosecuted in the United States. Amarin is also making significant progress
with its patent applications related to Vascepa in multiple jurisdictions
outsidethe United States, including the May 2013 patent grant by the European
Patent Office covering the use of Vascepa based on the results from the MARINE
trial.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

About the Slanmhor consortium

As previously disclosed, the Slanmhor consortium includes Slanmhor
Pharmaceuticals, Inc., Royal DSM, and Novasep Group S.A.S., each respectively
headquartered in Canada, Holland and France. Each of these companies has
extensive experience in providing omega-3 API manufacturing solutions.
Slanmhor, which heads the consortium, is a wholly-owned subsidiary of
Clearwater Fine Foods, Inc., a Canadian based investment holding company with
principal holdings that also include seafood harvesting, processing and
telecommunications. Novasep employs 1,200 people and has numerous FDA
inspected facilities and a global footprint that includes numerous API
manufacturing plants, biopharmaceutical production sites and equipment
manufacturing facilities. Its Mourenx, France, plant is intended to be the
first manufacturing plant used by the Slanmhor consortium to manufacturing
Vascepa API for Amarin.

Forward-looking statements

This press release contains forward-looking statements, including statements
about the manufacturing capacity and qualification of Vascepa suppliers,
potential product cost reductions from future supply sources, potential future
gross margins from the sale of Vascepa, the timing and likelihood of
regulatory submissions and approvals, the timing of manufacturing readiness
for supply and Amarin's ability to protect the commercial potential of
Vascepa. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that could
cause actual results to differ materially from those described or projected
herein include uncertainties associated generally with dependence on third
parties, research and development, clinical trials and related regulatory
submissions and approvals; cost containment efforts and factors contributing
to gross margins; events that could interfere with the issuance of a patent,
or once issued, the continued validity or enforceability of a patent; Amarin's
ability to maintain adequate patent protection and successfully enforce patent
claims against third parties; commercializing Vascepa without violating the
intellectual property rights of others; obtain regulatory exclusivity and take
advantage of manufacturing barriers to entry. A further list and description
of these risks, uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities and Exchange
Commission, including its most recent Annual Report on Form 10-Q. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (www.amarincorp.com), our investor
relations website (http://www.amarincorp.com/investor-splash.html), including
but not limited to investor presentations and investor FAQs,Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.